Seeking Alpha

Ad comm gives thumbs up to dalbavancin

  • Market chatter says today's Ad Comm vote for Durata Therapeutics' (DRTX -0.3%) dalbavancin was 12-0 recommending approval.
Comments (5)
  • GrowthGeek
    , contributor
    Comments (1097) | Send Message
    Look for share price to approach $20 in the near future.
    31 Mar, 04:08 PM Reply Like
  • Scrying Biotech
    , contributor
    Comments (1635) | Send Message
    Congratulations you! Well done.
    31 Mar, 08:32 PM Reply Like
  • forever5683
    , contributor
    Comments (106) | Send Message
    31 Mar, 04:11 PM Reply Like
  • rootbeer
    , contributor
    Comments (285) | Send Message
    Trius was bought for $707 million plus CVR's for a total possible value of $818 million. Market cap of DRTX is only about $350 million.
    31 Mar, 04:40 PM Reply Like
  • American3pt14
    , contributor
    Comment (1) | Send Message
    Dosing regimen can potentially save on a lot of healthcare costs. Decreased inpatient time (each day in hospital > $10,000). No PICC line placmeent needed on outpt discharge which saves a lot of money around visiting nurses, etc... Could be really helpful too in the future if they study in populations with infections such as endocarditis that require treatment for ~6 week with current abx; with this, one infusion week will save a lot of hassle, again, without the need for a PICC line which itself is a potential nydus of infection.
    31 Mar, 06:08 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector